BioStock: Lipum stepped into clinical stage in Q3

In Lipum’s quarterly report, CEO Einar Pontén says that more is going on at the company than ever before. Their drug candidate SOL-116 recently moved into clinical phase, the largest milestone to date for the Umeå-based development company. A one-year study is now underway to confirm the candidate’s safety and tolerability. BioStock contacted Pontén for a comment on the quarterly report and the transition to clinical stage.

Read the full article at biostock.se:

https://www.biostock.se/en/2022/11/lipum-stepped-into-clinical-stage-in-q3/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se